Diligence memo · auto-generated · as of July 2, 2026

Atlee Biotech, Inc.

Atlee Biotech, Inc. looks under-valued against its niche peers and is dormant on financing cadence.

DeprioritizeFinancing has gone silent well past the sector's normal cadence — treat as inactive until outside confirmation of a live operation.

Businessfiled

Atlee Biotech, Inc. operates in Biotechnology, based in DEL MAR.

Sub-sector tags: biotech.

No verified homepage on file yet — operating evidence is limited to the public record.

Capital & rounds (filed)filed

Atlee Biotech, Inc. has raised $250K in disclosed capital across 1 recorded round, aggregated from public filings. Its latest round is modeled as Pre-Seed (a round under $1.0M).

Largest single filing: $250K on 2021-12-20.

Most recent recorded round closed around 2021-12-20.

Valuation (modeled)modeled

Provath models Atlee Biotech, Inc. at approximately $5.5M (range $133K–$40M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.

Read: Under-valued. Modeled value is 0.36× the median modeled value of Pre-Seed Biotechnology companies in 2019–2021 (156 peers) — value vs value, same stage and era.

Financing rhythm & timingmixed

Last raise 4.5 yr ago; this sector typically re-raises about every 14 months.

Only one round on record and long silent — often defunct, acquired, or gone quiet.

Comparablesmixed

Capital scale ranks ahead of 6% of Biotechnology peers (4293 compared).

Modeled value ranks above 11% of those peers.

Closest niche peers: Crimson BioPharm Inc., Pinpoint Therapeutics Inc., Transplant Logistics & Informatics Llc, RNAissance AG LLC, Pylum Biosciences, Inc..

Peoplefiled

1 named person on file across officers, directors and signatories.

Risks & flagsmixed

Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.

No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.